Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castrationresistant prostate cancer-factors affecting diagnostic success

Radiology

Volumn 269, Issue 3, 2013, Pages 816-823

  Spritzer, Charles E ^a   Afonso, P Diana ^a,b   Vinson, Emily N ^a   Turnbull, James D ^a,c   Morris, Karla K ^a   Foye, Adam ^d   Madden, John F ^a   Choudhury, Kingshuk Roy ^a   Febbo, Phillip G ^a,d   George, Daniel J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Hospital Garcia Orta   (Portugal)

^c Department of Medicine   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; ZOLEDRONIC ACID;

AGED; ARTICLE; ATTENUATION; BONE MARROW BIOPSY; CANCER LOCALIZATION; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN TISSUE; ILIAC BONE; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; PELVIC GIRDLE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RNA ISOLATION; SACRUM; TUMOR VOLUME;

BIOPSY; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; DIPHOSPHONATES; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; MALE; PROSTATIC NEOPLASMS; RNA; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84890072338     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13121782     Document Type: Article

References (31)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-236.
2. Visakorpi T. The molecular genetics of prostate cancer. Urology 2003;62(5 Suppl 1):3-10.
3. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(5308):1943-1947.
4. Müller M, Rink K, Krause H, Miller K. PTEN/MMAC1 mutations in prostate cancer. Prostate Cancer Prostatic Dis 2000;3(S1):S32.
5. Rubin MA, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node-negative (pT2-3, N0) prostate cancer. Hum Pathol 2000;31(4):504-508.
6. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58(2):204-209.
7. Teng DHF, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997; 57(23):5221-5225.
8. Whang YE, Wu XY, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 1998;95(9):5246-5250.
9. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26(7):1148-1159.
10. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-655.
11. Bonds LA, Barnes P, Foucar K, Sever CE. Acetic acid-zinc-formalin: a safe alternative to B-5 fixative. Am J Clin Pathol 2005;124(2):205-211.
12. Wu JS, Goldsmith JD, Horwich PJ, Shetty SK, Hochman MG. Bone and soft-tissue lesions: what factors affect diagnostic yield of image-guided core-needle biopsy? Radiology 2008;248(3):962-970.
13. George D, Moul JW. Emerging treatment options for patients with castrationresistant prostate cancer. Prostate 2012; 72(3):338-349.
14. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363(18):1734-1739.
15. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-1765.
16. Berning W, Freyschmidt J, Ostertag H. Percutaneous bone biopsy, techniques and indications. Eur Radiol 1996;6(6):875-881.
17. Espinosa LA, Jamadar DA, Jacobson JA, et al. CT-guided biopsy of bone: a radiologist's perspective. AJR Am J Roentgenol 2008; 190(5):W283-W289.
18. Fraser-Hill MA, Renfrew DL. Percutaneous needle biopsy of musculoskeletal lesions. Effective accuracy and diagnostic utility. AJR Am J Roentgenol 1992;158(4):809-812.
19. Fraser-Hill MA, Renfrew DL, Hilsenrath PE. Percutaneous needle biopsy of musculoskeletal lesions. 2. Cost-effectiveness. AJR Am J Roentgenol 1992;158(4):813-818.
20. Hau A, Kim I, Kattapuram S, et al. Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions. Skeletal Radiol 2002; 31(6):349-353.
21. Leffler SG, Chew FS. CT-guided percutaneous biopsy of sclerotic bone lesions: diagnostic yield and accuracy. AJR Am J Roentgenol 1999;172(5):1389- 1392.
22. Logan PM, Connell DG, O'Connell JX, Munk PL, Janzen DL. Image-guided percutaneous biopsy of musculoskeletal tumors: an algorithm for selection of specific biopsy techniques. AJR Am J Roentgenol 1996;166(1):137-141.
23. Ruhs SA, el-Khoury GY, Chrischilles EA. A cost minimization approach to the diagnosis of skeletal neoplasms. Skeletal Radiol 1996; 25(5):449-454.
24. Vieillard MH, Boutry N, Chastanet P, Duquesnoy B, Cotten A, Cortet B. Contribution of percutaneous biopsy to the definite diagnosis in patients with suspected bone tumor. Joint Bone Spine 2005;72(1):53-60.
25. Welker JA, Henshaw RM, Jelinek J, Shmookler BM, Malawer MM. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer 2000;89(12):2677-2686.
26. Ayala AG, Zornosa J. Primary bone tumors: percutaneous needle biopsy. Radiologicpathologic study of 222 biopsies. Radiology 1983;149(3):675-679.
27. Kattapuram SV, Rosenthal DI. Percutaneous biopsy of skeletal lesions. AJR Am J Roentgenol 1991;157(5):935-942.
28. McCarthy EF. CT-guided needle biopsies of bone and soft tissue tumors: a pathologist's perspective. Skeletal Radiol 2007;36(3):181-182.
29. Berenson JR, Howell A, Porter L, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91(7):1191-1200. [Published correction appears in Cancer 2001; 91(10):1956.]
30. Saad F, Gleason DM, Murray R, et al. Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11): 879-882.
31. Saad FGD, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-1468.